The NHS in England has begun rolling out a groundbreaking 'rapid' immunotherapy injection for tens of thousands of cancer patients, drastically cutting the time required for treatment. The new injectable form of pembrolizumab, marketed as Keytruda, can be administered in as little as 60 seconds, a significant reduction compared to the intravenous infusion method which typically takes 30 to 60 minutes.
This innovative treatment is anticipated to benefit a substantial number of patients across England, targeting over a dozen different types of cancer. These include common forms such as lung cancer, head and neck cancer, and melanoma. The introduction of this rapid jab is a pivotal development in cancer care, offering both practical advantages for patients and operational efficiencies for the health service.
Pembrolizumab is a type of immunotherapy that works by harnessing the body's own immune system to detect and fight cancer cells. It is a monoclonal antibody that blocks the PD-1 pathway, a mechanism used by cancer cells to evade immune detection. While the active drug remains the same, the method of delivery has been transformed from an intravenous drip into a subcutaneous injection, making the process much quicker and less intrusive for patients.
The shift to a 60-second injection is expected to free up thousands of hours of valuable time for NHS cancer teams. This includes doctors, nurses, and pharmacists who previously dedicated significant time to preparing and monitoring intravenous infusions. By streamlining the administration process, healthcare professionals will have more capacity to care for other patients, manage complex cases, or provide additional support and information to those undergoing treatment.
For patients, the practical implications are considerable. Spending less time in hospital for each treatment session can significantly improve their quality of life, reduce travel burdens, and minimise disruption to daily routines. The psychological benefit of a quicker, less invasive procedure can also contribute to a more positive treatment experience during what is often a challenging period.
NHS England has been actively working with pharmaceutical companies to secure access to innovative treatments. This rollout aligns with the NHS Long Term Plan's commitment to delivering more convenient and personalised care closer to patients' homes where appropriate, and leveraging technological advancements to improve health outcomes.
Source: NHS England